Osimertinib for Advanced EGFR-positive NSCLC Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Osimertinib for Advanced EGFR-positive NSCLC Patients — Stella

Recruiting

Back to EGFR Positive Non-small Cell Lung Cancer trials

Trial locations(1 site)

Singapore

National University Hospital, Singapore

Key details

Sponsor

National University Hospital, Singapore

Enrollment target

~58 participants

Started

July 2021

Primary completion

June 2026

Age range

21 Years – 99 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov